Your session is about to expire
← Back to Search
NAD+ Augmentation for Acute Kidney Injury (NACAM Trial)
NACAM Trial Summary
This trial was designed to study the effectiveness of a drug called Nam for preventing acute kidney injury in patients undergoing heart surgery.
NACAM Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowNACAM Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 1 trial • 40 Patients • NCT00691210NACAM Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have certain health conditions or risk factors that could make surgery risky for your heart, such as heart valve surgery, kidney function below a certain level, weak heart pumping function, history of heart failure, diabetes requiring insulin, diabetes not requiring insulin with certain kidney function test results, low red blood cell count, previous heart bypass surgery, or being 65 years or older.I have had a kidney transplant.I am having heart surgery without using a heart-lung machine.My kidney function was reduced before surgery, as shown by a creatinine test.I have end-stage renal disease.I have had heart surgery, including valve repair or replacement.I am over 18 and scheduled for heart surgery with CPB, at high risk for heart-related surgery complications.I am currently detained or incarcerated.I need urgent heart surgery.
- Group 1: Oral niacinamide
- Group 2: Matched placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any opportunities for individuals to join this investigation?
"According to clinicaltrials.gov, this experiment is currently recruiting subjects. The study was initially advertised on September 13th 2021 and the latest update occurred on June 27th 2022."
To what conditions is Niacinamide typically applied therapeutically?
"Niacinamide is often administered for nutritional supplementation, but it also has clinical applications in dietary and vitamin deficiencies as well as macrocytic anemia."
What is the enrollment cap for this clinical trial?
"Affirmative. Clinicaltrials.gov reveals that this medical trial, which was initially made available on September 13th 2021, is currently enrolling patients . Approximately 304 test subjects need to be recruited from 1 research facility."
Does the Food and Drug Administration sanction Niacinamide for therapeutic use?
"At Power, we rated Niacinamide's safety as a 2 since there is only data supporting its security but no evidence that it has any therapeutic benefits."
Share this study with friends
Copy Link
Messenger